Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 278 No 7447 p416
14 April 2007

This article
Reprint   Photocopy

  Acrobat Reader


News summary


£9.5m patient safety boost as new research centres established

Two expert research centres have been established to drive improvements in the safety, quality and effectiveness of NHS services.

The centres will be supported by £9.5m of Government funding over five years. One, based at St Mary’s NHS Trust, London, and Hammersmith Hospitals NHS Trust, London, will look at the safety, quality and reliability of the technology used by the NHS and the role of staff and IT resources in improving patient safety. The other, based at King’s College Hospital NHS Trust, London, will investigate emerging health technologies and look at ways in which services and staff can be organised to improve patient safety.

Research grants worth up to £800,000 have also been awarded to Bradford Teaching Hospitals NHS Foundation Trust and University Hospitals of Morecombe Bay NHS Trust to support research on patient safety.

Bryony Dean Franklin, director of the centre for medication safety and service quality at Hammersmith Hospitals NHS Trust, is joint programme lead for the research streams at the Hammersmith Hospitals NHS Trust centre.

Professor Dean Franklin told The Journal that one of the first projects the team will undertake is to evaluate a robot for cytotoxic compounding. “A robot is currently being installed within the pharmacy department at Hammersmith Hospitals NHS Trust,” she explained. “We plan to carry out a formal evaluation of that initiative, rather than just installing the robot and seeing how we get on.”

The group will also look at the computerised selection of drugs and at systems to highlight test results to clinical pharmacists, she said. “A PDA [personal digital assistant], or something similar, would be used to highlight results or drug levels that are outside a pre-defined range. That would enable clinical pharmacists to have the results immediately wherever they are and be able to act on them.”

Back to Top


©The Pharmaceutical Journal